De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Medtronic Beheer
Beheer criteriumcontroles 2/4
De CEO Medtronic's is Geoff Martha, benoemd in Apr2020, heeft een ambtstermijn van 4.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 20.08M, bestaande uit 6.7% salaris en 93.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde $ 6.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 9.8 jaar.
Belangrijke informatie
Geoff Martha
Algemeen directeur
US$20.1m
Totale compensatie
| Percentage CEO-salaris | 6.7% |
| Dienstverband CEO | 4.5yrs |
| Eigendom CEO | 0.006% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 9.8yrs |
Recente managementupdates
Recent updates
An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued
Sep 30
Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks
Sep 16Medtronic: An Undervalued Stock With Durable Competitive Advantages
Sep 16Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Sep 05Medtronic: Is The Company Back?
Aug 26Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Medtronic: The Tide Is Turning
Aug 24Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Aug 21Medtronic: Dark Clouds Are Clearing - Outperformance Ahead
Aug 14Return Trends At Medtronic (NYSE:MDT) Aren't Appealing
Aug 11Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth
Jul 15Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?
Jul 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jul 26 2024 | n/a | n/a | US$4b |
| Apr 26 2024 | US$20m | US$1m | US$4b |
| Jan 26 2024 | n/a | n/a | US$4b |
| Oct 27 2023 | n/a | n/a | US$4b |
| Jul 28 2023 | n/a | n/a | US$4b |
| Apr 28 2023 | US$15m | US$1m | US$4b |
| Jan 27 2023 | n/a | n/a | US$4b |
| Oct 28 2022 | n/a | n/a | US$4b |
| Jul 29 2022 | n/a | n/a | US$5b |
| Apr 29 2022 | n/a | n/a | US$5b |
| Jan 28 2022 | n/a | n/a | US$5b |
| Oct 29 2021 | n/a | n/a | US$5b |
| Jul 30 2021 | n/a | n/a | US$4b |
| Apr 30 2021 | US$18m | US$1m | US$4b |
| Jan 29 2021 | n/a | n/a | US$3b |
| Oct 30 2020 | n/a | n/a | US$4b |
| Jul 31 2020 | n/a | n/a | US$4b |
| Apr 24 2020 | US$6m | US$905k | US$5b |
| Jan 24 2020 | n/a | n/a | US$5b |
| Oct 25 2019 | n/a | n/a | US$5b |
| Jul 26 2019 | n/a | n/a | US$4b |
| Apr 26 2019 | US$4m | US$693k | US$5b |
Compensatie versus markt: De totale vergoeding ($USD 20.08M ) Geoff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).
Compensatie versus inkomsten: De vergoeding van Geoff is het afgelopen jaar met meer dan 20% gestegen.
CEO
Geoff Martha (54 yo)
4.5yrs
Tenure
US$20,084,630
Compensatie
Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.5yrs | US$20.08m | 0.0060% $ 6.8m | |
| Executive VP & President of Cardiovascular Portfolio | no data | US$6.55m | 0.0021% $ 2.4m | |
| Executive VP & President of Neuroscience Portfolio | 4.9yrs | US$6.44m | 0.00092% $ 1.0m | |
| Executive Vice President of Global Operations & Supply Chain | 3.5yrs | US$7.66m | 0.0015% $ 1.7m | |
| Senior Vice President of Global Financial Planning and Analysis & Interim CFO | less than a year | geen gegevens | 0.00045% $ 509.4k | |
| Senior Vice President of Global Operations and Business Services | 8yrs | geen gegevens | geen gegevens | |
| Senior VP | 3.3yrs | geen gegevens | 0.0022% $ 2.5m | |
| Senior VP and Chief Technology & Innovation Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Senior VP and Chief Scientific & Medical Officer | 2.5yrs | geen gegevens | geen gegevens | |
| VP & Head of Investor Relations | 9.3yrs | geen gegevens | geen gegevens | |
| Executive VP | 2.7yrs | US$11.72m | 0.0019% $ 2.1m | |
| Senior VP & Chief Communications Officer | 3.8yrs | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MDT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.9yrs | US$20.08m | 0.0060% $ 6.8m | |
| Independent Director | 11.8yrs | US$365.06k | 0.0012% $ 1.3m | |
| Independent Director | 17.8yrs | US$350.06k | 0.0015% $ 1.7m | |
| Independent Director | 9.8yrs | US$385.06k | 0.0034% $ 3.8m | |
| Lead Independent Director | 9.8yrs | US$410.06k | 0.0028% $ 3.2m | |
| Independent Director | 24.8yrs | US$375.06k | 0.0031% $ 3.5m | |
| Independent Director | 5.6yrs | US$370.06k | 0.00048% $ 543.3k | |
| Independent Director | 10.8yrs | US$370.06k | 0.0010% $ 1.2m | |
| Independent Director | 2.3yrs | US$350.06k | 0.00012% $ 135.8k | |
| Independent Director | 4.1yrs | US$370.06k | 0.00032% $ 362.2k | |
| Independent Director | 1.3yrs | US$306.97k | 0% $ 0 |
9.8yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MDT wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.8 jaar).